Bristol-Myers Inks $440M Sales Deal With Reckitt Benckiser
Under the terms of the three-year deal, Reckitt Benckiser will pay Bristol-Myers $438 million upfront for the rights to sell, distribute and market several over-the-counter medications Bristol-Myers currently sells in Mexico, Brazil and other parts of Latin America, with an option to purchase the drugs at the end of the...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login